EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Benefit‐to‐radiation‐risk of low‐dose computed tomography lung cancer screening

R Edward Hendrick iD, Robert A Smith iD

Cancer · 2024

DOI: 10.1002/cncr.34855 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von R Edward Hendrick und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Lung Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The US National Lung Screening Trial (NLST) and Dutch‐Belgian NELSON randomized controlled trials have shown significant mortality reductions from low‐dose computed tomography (CT) lung cancer screening (LCS). NLST, ITALUNG, and COSMOS trials have provided detailed dosimetry data for LCS.

Methods

LCS trial mortality benefit results, organ dose and effective dose data, and Biological Effects of Ionizing Radiation, Report VII (BEIR VII) organ dose‐to‐cancer‐mortality risk data are used to estimate benefit‐to‐radiation‐risk ratios of the NLST, ITALUNG, and COSMOS trials. Data from those trials also are used to estimate benefit‐to‐radiation‐risk ratios for longer‐term LCS corresponding to scenarios recommended by United States Preventive Services Task Force and the American Cancer Society.

Results

Including only screening doses, NLST benefit‐to‐radiation‐risk ratios are 12:1 for males, 19:1 for females, and 16:1 overall. Including both screening and estimated follow‐up doses, benefit‐to‐radiation‐risk ratios for NLST are 9:1 for males, 13:1 for females, and 12:1 overall. For the ITALUNG trial, the benefit‐to‐radiation‐risk ratio is 58–63:1. For the COSMOS trial, assuming sex‐specific mortality benefits like those of the NELSON trial, the benefit‐to‐radiation‐risk ratio is 23:1. Assuming a conservative 20% mortality benefit, annual screening in people 50–79 years old with a 20+ pack‐year history of smoking has benefit‐to‐radiation‐risk ratios of 23:1 (with follow‐up doses adding 40% to screening doses) to 29:1 (with follow‐up adding 10%) based on COSMOS dose data.

Conclusions

Based on linear, no threshold BEIR VII dose‐risk estimates, benefit‐to‐radiation‐risk ratios for LCS are highly favorable. Results emphasize the importance of using modern CT technologies, maintaining low diagnostic follow‐up rates, and minimizing both screening and diagnostic follow‐up doses. Plain Language Summary The benefits of lung cancer screening significantly outweigh estimates of future harms associated with exposure to radiation during screening and diagnostic follow‐up examinations. Our findings emphasize the importance of lung cancer screening practices using state‐of‐the‐art computed tomography scanners and specialized low‐dose lung screening and diagnostic follow‐up techniques.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsMaleFemaleHumansUnited StatesMiddle AgedAgedEarly Detection of CancerRisk AssessmentTomography, X-Ray ComputedLungMass Screening

Stichwörter der Autor:innen

benefit-to-riskcomputed tomographydeaths avertedlung cancerlung cancer screeningradiation risks

Autor:innen und Institutionen

  • Department of Radiology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.
  • Early Cancer Detection Science Department, American Cancer Society, Kennesaw, Georgia, USA.

ORCID-Profile: R Edward Hendrick, Robert A Smith

Zitieren

APA

Hendrick, R. E., & Smith, R. A. (2024). Benefit‐to‐radiation‐risk of low‐dose computed tomography lung cancer screening. Cancer. https://doi.org/10.1002/cncr.34855

Vancouver

Hendrick RE, Smith RA. Benefit‐to‐radiation‐risk of low‐dose computed tomography lung cancer screening. Cancer. 2024. doi:10.1002/cncr.34855

BibTeX
@article{Hendrick2024,
  author = {Hendrick, R Edward and Smith, Robert A},
  title = {Benefit‐to‐radiation‐risk of low‐dose computed tomography lung cancer screening},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.34855}
}
Kostenlos starten →